HealthCare Global Outlines Mid-Teens Revenue Growth And 21-22% EBITDA Margin Targets

Market snapshot: HealthCare Global Enterprises (HCG) has reiterated its long-term operational and capacity expansion targets during its Q1 FY27 earnings call. The specialty oncology hospital chain is guiding for steady mid-teens top-line growth while working toward significant profitability enhancements, targeting EBITDA margins of 21-22% in the near term and 25% within five years. To support this growth, HCG plans to add 815 beds through FY30, leveraging capital-efficient brownfield projects for the majority of the expansion.

Data Snapshot

• The company expects mid-teens revenue growth over the medium term, driven by capacity expansion and case mix improvements.
• Management has guided for EBITDA margins of 21-22% in the next two years and 25% over the next four to five years.
• Capacity expansion includes adding 65 beds in FY27, 520 beds in FY28-FY29, and 230 beds in FY30, totaling 815 beds.
• Approximately 60% of the planned 815 beds will be executed via brownfield projects to optimize execution timelines and lower CapEx.

What's Changed

• Guided EBITDA margins of 21-22% in two years represent an uptick compared to the 19.4% adjusted EBITDA margin recorded in Q1 FY27 (derived: +160 to +260 bps improvement).
• Completed divestment of the non-core fertility business (Milann) in June 2026, allowing full capital and operating focus to pivot to core oncology specialty operations.

Key Takeaways

• Targeted Bed Execution: Out of the 815 beds, the near-term addition of 65 beds in FY27 is followed by a heavy execution phase of 520 beds in FY28-FY29, and 230 beds in FY30.
• Margin Improvement Levers: Margin expansion is structurally tied to payor mix optimization (increasing cash and private payors while reducing low-margin government schemes), clinical complexity, and declining start-up losses at new facilities.
• Efficiency in Expansion: Over 60% brownfield expansion significantly reduces capital requirements, allowing for higher Return on Capital Employed (ROCE) as the centers mature.

SAHI Perspective

HCG is shifting focus toward high-quality earnings over pure volume expansion. The divestment of the barely profitable Milann fertility business and the strategic choice of 60% brownfield bed additions highlight disciplined capital allocation. By prioritizing high-complexity oncology therapies and targeting non-institutional payor mix (which reached 69% in Q1 FY27), HCG is building a structurally superior margin profile that makes its 21-22% medium-term margin guidance highly credible.

Market Implications

Steady execution of the 815-bed pipeline and gradual reduction in start-up losses at newly opened centers, like the Hebbal facility in North Bengaluru, will act as major positive catalysts. Over the medium term, as higher-margin adaptive clinical technologies (such as the newly commissioned MR-Linac) drive complex case volumes, HCG is well-positioned to command a premium valuation within the specialized healthcare sector.

Trading Signals

Market Bias: Bullish

Robust financial foundations in Q1 FY27, with revenue growing 13.4% YoY to ₹695.1 cr and adjusted EBITDA rising 20% YoY to ₹133.9 cr, combined with highly structured margin targets of 21-22% in two years, support a positive outlook.

Overweight: Healthcare, Hospitals

Trigger Factors:

• Consistent execution of the 65-bed addition in FY27.
• Reduction in start-up losses at the Hebbal (North Bengaluru) facility.
• Retention of non-institutional payor mix above 69%.

Time Horizon: Medium-term (3-12 months)

Industry Context

The single-specialty hospital segment in India continues to witness strong tailwinds due to rising cancer incidences, higher health insurance penetration, and a clear shift toward tertiary and quaternary care providers. Specialized oncology platforms are achieving higher realizations per occupied bed, which helped HCG sustain average revenue per patient (ARPP) at ₹85,943 in Q1 FY27, even as general medical device players face global margin pressures.

Key Risks to Watch

• Execution risk associated with commissioning 520 beds during FY28-FY29.
• Potential regulatory intervention on specialized treatment pricing or expansion of mandatory price caps.
• Inflationary pressure on sourcing high-caliber clinical talent and specialized medical equipment.

Recent Developments

HCG's Board approved a ₹16 cr cash investment in its wholly owned subsidiary HCG Rajkot Hospitals LLP on August 6, 2026, to fund working capital requirements and repay dues. Additionally, the company commissioned Karnataka's first Elekta Unity MR-Linac radiation therapy platform at its North Bengaluru facility in July 2026, enhancing clinical capabilities.

Closing Insight

HCG's guidance presents a balanced model of expansion and financial discipline, where capital-efficient brownfield projects and high-value clinical focus are primed to unlock structural margin expansion.

High Performance Trading with SAHI.